Updated on 10 April 2014
Dr Marcus Schabacker, vice president, R&D, medical products, Baxter International Inc
Singapore: In this role, he is instrumental in aligning R&D and commercial opportunities to accelerate innovation at Baxter and enhance care for patients globally.
Dr Schabacker holds an MD and a Doctorate in anesthesia from Medical University of Lübeck in Germany, and certifications in anesthesiology, disaster medicine and emergency medicine.
Q: India has taken a beating in the area of clinical trials. Almost half of the clinical trials in India is halted. In such scenario, why do you think establishing a Baxter Global Research Center (BGRC) in India with Syngene would contribute to your R&D expansion strategy?
Dr Schabacker: Many R&D activities are required prior to the need for clinical trials, and Baxter's global research center in India is very focused on these R&D activities.
In the short term, clinical activities are not planned in BGRC, though we will continue to stay in tune with government directives for clinical activities in India for long-term consideration.